Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Parisi

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 10, 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studiesAlessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
Journal of the National Cancer Institute|April 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort studyLuca Cantini, Francesco Paoloni, Federica Pecci, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|February 10, 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studiesAlessandro Parisi, Blandine Delaunay, Giada Pinterpe, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2024
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinomaLorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, et al.
Journal of the National Cancer Institute|April 12, 2023
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort studyLuca Cantini, Francesco Paoloni, Federica Pecci, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2022
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancerDavid J Pinato, Daniela Ferrante, Juan Aguilar-Company, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Pageof 11